Novo Nordisk | Euronews

English

Markets

Novo Nordisk shares jump after Wegovy price cuts announced

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its weight-loss treatment Wegovy.

Health news

Obesity drugs could help curb alcohol cravings, study suggests

The new findings add to growing evidence that the medicines could help people with alcohol addiction.

Business

Novo Nordisk shares surge as weight loss treatments boost profits

Demand for weight-loss drugs surged throughout 2024, outpacing supply for most of the year. In December, Novo Holdings, an investment foundation of Novo Nordisk, acquired three manufacturing sites in Catalent to expand its production capacity.

Health news

Scientists unveil benefits and risks of blockbuster weight-loss drugs

While weight-loss drugs were linked to lower risk of some conditions, they were also associated with some adverse health outcomes.

ADVERTISEMENT

Business

Novo Nordisk shares plunge on the back of disappointing trial results

Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall wiped out €90bn in market valuation on Friday.

Business

Eli Lilly shares rise as Zepbound weight-loss test shows solid success

Lilly said patients taking Zepbound lost about 20% of their weight on average compared with nearly 14% for Wegovy. The drug maker also said more patients taking Zepbound achieved at least 25% weight loss.

Health news

Weight loss drugs could help fight chronic kidney disease, study finds

Researchers said the drugs could make a major difference for chronic kidney disease patients by helping to reduce other risk factors.

Health news

Teens on anti-obesity drugs less likely to consider or attempt suicide

Researchers said the drugs don’t appear to raise the risk of suicidal thoughts or actions for young people but also urged caution in interpreting the results.

Health news

France to patients: Take weight loss drug Wegovy on your own dime

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.

Business

Novo Nordisk boss in US grilling over prices for weight-loss drugs

Novo Nordisk has been criticised by US politicians for the high pricing of its popular weight-loss and diabetes drugs. But CEO Lars Fruergaard Jørgensen has defended the company, attributing the elevated prices to "structural issues" within the US healthcare system.

Business

Weight loss market: Eli Lilly and Novo Nordisk's rivals muscle in

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up to release their own treatments, aiming to challenge the two industry leaders.

Health news

Weight-loss drug 'safe and effective' for kids as young as 6

Novo Nordisk asked US regulators to approve the drug for children ages 6 to 11. In the EU, it's available for adolescents as young as 12.

Business

Novo Nordisk: Earnings trimmed as rivals seek to enter market

Novo Nordisk missed earnings expectations in the second quarter due to growing competition and increased costs from capacity expansions. The company also downgraded its profit outlook for 2024.

Business

Investors look to weight loss drugs to boost Novo Nordisk growth

Novo Nordisk is releasing its second-quarter earnings on Wednesday, with analysts expecting more than 20% growth driven by Ozempic and Wegovy sales. However, the company faces challenges from more competition.

Health news

New study sheds light on illegal online pharmacies selling semaglutide

Researchers looked at the composition of online purchases of semaglutide, the popular drug usually prescribed for diabetes or obesity.

Business

Roche plans speedy weight-loss drug launch to catch up with rivals

Roche believes its anti-obesity drugs could have advantages over other more established rivals such as Eli Lilly and Novo Nordisk through ease of scalability that will allow it to meet increased demand.

No Comment

Novo Nordisk faces another fire

A major fire has broken out at a building at the head quarters of Danish pharmaceutical firm Novo Nordisk

Health news

'Ozempic breasts': What are the side effects of weight loss drugs?

While many people suffering from obesity have been using Ozempic to help with weight loss, health professionals are warning of potential side effects.

Health news

Ozempic found to cut heart disease and keep weight off for four years

New analyses of a large trial presented at the European Congress on Obesity showed the clear benefits of the popular weight-loss drug.

Business

Novo Nordisk owner invests millions in quantum computing

Novo Holdings, the parent company of the maker of weight-loss drugs Ozempic and Wegovy, is investing millions to create a global innovation hub for quantum technology in Denmark.